| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 8,010 | 8,680 | 11,240 | 13,600 | 1,590 |
| Sales Growth | -7.72% | -22.78% | -17.35% | +755.35% | -51.52% |
| Net Income | -7,130 | -11,390 | -46,210 | -61,930 | -12,330 |
| Net Income Growth | +37.40% | +75.35% | +25.38% | -402.27% | +47.93% |
Vyome Holdings Inc
(HIND)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31